A Phase 2 interventional study of GSK3810109A and Dolutegravir+lamivudine SOC regimen in HIV Infections, sponsored by ViiV Healthcare. Completed at 24 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 115th largest by enrollment of the 210 interventional ones that give a count, is one of 7 that started in 2021, is one of 48 in phase 2, and was the 222nd registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in Romania, South Africa, Uganda
ViiV Healthcare · Sites in Netherlands
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 85 · Phase 2 53 · Phase 3 68 · Phase 4 18
First in 1994; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 82 across the 210 interventional studies, 328 across the 14 observational. Of the 230 that completed or were terminated, 95 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
6 of the studies in HIV Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT07934719ViiV HealthcareMass Balance and Absolute Bioavailability of [14C]-VH4011499 | 2027-02-18 |
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
| NCT07939594ViiV HealthcareAn Evaluation of the Potential for VH4011499 Drug-drug-interactions | 2027-03-12 |
| NCT07525544ViiV HealthcareA Study to Investigate the Safety and PK of VH4770359 in Healthy Participants | 2027-05-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 266 studies in HIV Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate antiviral activity, efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3810109A in HIV-1 infected treatment naive adults. Participants will receive a single dose of GSK3810109A administered either intravenously (IV) or subcutaneously (SC). The study includes a screening phase, a randomized monotherapy phase and a standard of care follow-up phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rescreening is allowed after treatment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with human immunodeficiency viruses-1 (HIV-1) received GSK3810109A as a single intravenous (IV) infusion of 40 milligrams per kilogram (mg/kg) dose based on individual bodyweight on Day 1 in part 1.
Biological: GSK3810109A
Participants with HIV-1 received GSK3810109A as a single IV infusion of 280 mg dose on Day 1 in part 1.
Biological: GSK3810109A
Participants with HIV-1 received GSK3810109A as a single IV infusion of 700 mg dose on Day 1 in part 2. This included dose level determined based on the data of part 1.
Biological: GSK3810109A
Participants with HIV-1 received GSK3810109A as a single IV infusion of 70 mg dose on Day 1 in part 2. This included dose level determined based on the data of part 1.
Biological: GSK3810109A
Participants with HIV-1 received GSK3810109A as a subcutaneous (SC) injection of total 700 mg dose administered as three equally divided SC injections of 2.33 mL each (approximately 7 mL) in quick succession at same time on Day 1 in part 2. This included dose level determined based on the data of part 1.
Biological: GSK3810109A
Participants who completed the monotherapy phase of treatment of GSK3810109A 40mg/kg IV entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.
Biological: Dolutegravir+lamivudine SOC regimen
Participants who completed the monotherapy phase of treatment of GSK3810109A 280 mg IV entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.
Biological: Dolutegravir+lamivudine SOC regimen
Participants who completed the monotherapy phase of treatment of GSK3810109A 700 mg IV entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.
Biological: Dolutegravir+lamivudine SOC regimen
Participants who completed the monotherapy phase of treatment of GSK3810109A 70 mg IV entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.
Biological: Dolutegravir+lamivudine SOC regimen
Participants who completed the monotherapy phase of treatment of GSK3810109A 700 mg SC entered SOC phase to receive dolutegravir + lamivudine regimen as a SOC treatment on SOC Day 1 if deemed appropriate by the investigator and consistent with local guidelines.
Biological: Dolutegravir+lamivudine SOC regimen
GSK3810109A available as sterile aqueous solution.
Dolutegravir+lamivudine regimen administered in consistence with investigator input and local guidelines
Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase
Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. Maximum decline from baseline in plasma HIV-1 RNA were measured in participants. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
Time frame: Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase
Number of Participants With Adverse Events (AEs) - Monotherapy Phase
An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
Time frame: Up to Day 84 or end of Monotherapy Phase
Number of Participants With Worst-case Maximum Grade 2-4 Increase in Post-baseline Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Compared to the Baseline Values - Monotherapy Phase
Blood samples were collected for the analysis of ALT and AST parameters. The parameters ALT and AST were graded using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Data of number of participants with 2-4 grade increase at worst-case post-baseline (maximum grade increase post-baseline) is presented. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
Time frame: Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase
Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Findings - Monotherapy Phase
A 12-lead ECG were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using Fridericia's formula (QTcF) intervals. ECG findings were categorized as normal, abnormal clinically significant (CS) and abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal (CS and NCS) ECG findings are presented. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
Time frame: Up to Day 84 or end of Monotherapy Phase
Number of Participants With Grade 2-4 Injection Site Reactions (ISR) - Monotherapy Phase
Number of participants with grade 2-4 injection site reactions are presented. The ISR were graded using the Division of Acquired immunodeficiency syndrome (DAIDS) criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates more severe condition. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
Time frame: Up to Day 84 or end of Monotherapy Phase
Area Under the Plasma Concentration-time Curve From Time Zero to the Day 14 (AUC [0-14]) of GSK3810109A - Monotherapy Phase
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3810109A.
Time frame: Pre-dose (Day 1), 3 and 24 hours post-dose on day 1, days 3, 6, 9, 11, and 14
Maximum Observed Plasma Concentration (Cmax) of GSK3810109A - Monotherapy Phase
Cmax is defined as maximum observed concentration of GSK3810109A.
Time frame: Pre-dose (Day 1), 3 and 24 hours post-dose on day 1, days 3, 6, 9, 11, and 14
Time to Reach Maximum Observed Plasma Concentration (Tmax) of GSK3810109A - Monotherapy Phase
Tmax is defined as time to reach Cmax
Time frame: Pre-dose (Day 1), 3 and 24 hours post-dose on day 1, days 3, 6, 9, 11, and 14
Plasma Concentration at Day 14 (C14) of GSK3810109A - Monotherapy Phase
Blood samples were collected at indicated time point for pharmacokinetic analysis of GSK3810109A.
Time frame: At Day 14
Change From Baseline in Log10 Plasma HIV-1 RNA Relative to Cmax - Monotherapy Phase
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. Statistical analysis for relationship between PK parameter (Cmax) and PD measure (change from baseline in logarithm to base 10 (log10) values for plasma HIV-1 RNA) were explored using an Emax non-linear model. The model parameters estimated included: maximum response (Emax), PK parameter value that attains 50 percent (%) of the maximal effect (EC50) and residual variability (s2e). End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
Time frame: Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase
Absolute Values of Cluster of Differentiation 4 Plus (CD4+) and CD8+ T Cell Counts - Monotherapy Phase
Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
Time frame: From Day 1 (Baseline) and up to Day 84 or end of Monotherapy Phase
Absolute Values of CD4+ and CD8+ T Cell Counts - SOC Phase
Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry.
Time frame: Up to Week 48 (SOC Phase)
Change From Baseline in CD4+ and CD8+ T Cell Counts - Monotherapy Phase
Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
Time frame: Up to Day 84 or end of Monotherapy Phase (compared with baseline [Day 1])
Change From Baseline in CD4+ and CD8+ T Cell Counts - SOC Phase
Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry.
Time frame: Up to Week 48 (SOC Phase)
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against GSK3810109A - Monotherapy Phase
Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
Time frame: At Day 1 and Day 84 or end of Monotherapy Phase
Number of Participants With Positive ADAs Against GSK3810109A - SOC Phase
Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays.
Time frame: At Week 48 (SOC Phase)
Titers of Positive ADAs Against GSK3810109A - Monotherapy Phase
Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
Time frame: At Day 84 or end of Monotherapy Phase
Titers of Positive ADAs Against GSK3810109A - SOC Phase
Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays.
Time frame: At Week 48 (SOC Phase)
62 unique participants were enrolled in the study including one participant that was re-screened. This re-screened participant signed two different informed consent forms, therefore this participant was counted as enrolling twice.
| Milestone | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) | SOC - GSK3810109A 40mg/kg IV | SOC - GSK3810109A 280 mg IV | SOC - GSK3810109A 700 mg IV | SOC - GSK3810109A 70 mg IV | SOC - GSK3810109A 700 mg SC |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 8 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) | SOC - GSK3810109A 40mg/kg IV | SOC - GSK3810109A 280 mg IV | SOC - GSK3810109A 700 mg IV | SOC - GSK3810109A 70 mg IV | SOC - GSK3810109A 700 mg SC |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 16 | 16 | 16 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 16 | 16 | 16 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) | SOC - GSK3810109A 40mg/kg IV | SOC - GSK3810109A 280 mg IV | SOC - GSK3810109A 700 mg IV | SOC - GSK3810109A 70 mg IV | SOC - GSK3810109A 700 mg SC |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 8 | 6 | 16 | 16 | 16 |
| Completed | 0 | 0 | 0 | 0 | 0 | 7 | 5 | 14 | 16 | 16 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. Maximum decline from baseline in plasma HIV-1 RNA were measured in participants. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
| Copies per milliliter (copies/mL) | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| Baseline (Day 1) | 12258.5 (1351 to 173710) | 30833.0 (5938 to 104585) | 25466.0 (7180 to 110387) | 25689.5 (7225 to 683576) | 23146.0 (131 to 181078) |
| Maximum decline from baseline (up to Day 84/end of Monotherapy Phase) | -12014.5 (-171577 to -1312) | -26826.5 (-103583 to -5899) | -25966.0 (-107218 to -6944) | -14720.5 (-197793 to -4382) | -12584.0 (-178423 to -69) |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
| Participants | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) - Monotherapy Phase | 7 | 4 | 9 | 8 | 11 |
Blood samples were collected for the analysis of ALT and AST parameters. The parameters ALT and AST were graded using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Data of number of participants with 2-4 grade increase at worst-case post-baseline (maximum grade increase post-baseline) is presented. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
| Participants | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| ALT, Baseline, Grade 0 | 8 | 6 | 15 | 12 | 15 |
| ALT, Baseline, Grade 1 | 0 | 0 | 1 | 2 | 1 |
| ALT, Baseline, Grade 2 | 0 | 0 | 0 | 2 | 0 |
| ALT, Baseline, Grade 3 | 0 | 0 | 0 | 0 | 0 |
| ALT, Baseline, Grade 4 | 0 | 0 | 0 | 0 | 0 |
| ALT, Worst Case Post-Baseline, Increase to Grades 2 to 4 | 0 | 0 | 0 | 0 | 0 |
| ALT, Worst Case Post-Baseline, Increase to Grades 3 to 4 | 0 | 0 | 0 | 0 | 0 |
| AST, Baseline, Grade 0 | 8 | 6 | 15 | 14 | 16 |
| AST, Baseline, Grade 1 | 0 | 0 | 0 | 1 | 0 |
| AST, Baseline, Grade 2 | 0 | 0 | 1 | 1 | 0 |
| AST, Baseline, Grade 3 | 0 | 0 | 0 | 0 | 0 |
| AST, Baseline, Grade 4 | 0 | 0 | 0 | 0 | 0 |
| AST, Worst Case Post-Baseline, Increase to Grades 2 to 4 | 1 | 0 | 1 | 0 | 1 |
| AST, Worst Case Post-Baseline, Increase to Grades 3 to 4 | 1 | 0 | 1 | 0 | 0 |
A 12-lead ECG were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using Fridericia's formula (QTcF) intervals. ECG findings were categorized as normal, abnormal clinically significant (CS) and abnormal not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal (CS and NCS) ECG findings are presented. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
| Participants | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| Abnormal - Clinically Significant | 0 | 0 | 0 | 0 | 0 |
| Abnormal - Not Clinically Significant | 3 | 2 | 3 | 4 | 7 |
Number of participants with grade 2-4 injection site reactions are presented. The ISR were graded using the Division of Acquired immunodeficiency syndrome (DAIDS) criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates more severe condition. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
| Participants | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| Number of Participants With Grade 2-4 Injection Site Reactions (ISR) - Monotherapy Phase | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3810109A.
| Day *microgram/millilitre (day*ug/mL) | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Day 14 (AUC [0-14]) of GSK3810109A - Monotherapy Phase | 5346.3194 ± 29.6508 | 690.8944 ± 53.2785 | 1181.1688 ± 24.4990 | 212.6213 ± 79.1478 | 493.0579 ± 55.0909 |
Cmax is defined as maximum observed concentration of GSK3810109A.
| Microgram/millilitre (μg/mL) | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of GSK3810109A - Monotherapy Phase | 1131.5000 ± 329.91168 | 131.1500 ± 86.65425 | 243.0625 ± 57.37301 | 42.7688 ± 54.32691 | 45.0938 ± 20.48930 |
Tmax is defined as time to reach Cmax
| Days | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of GSK3810109A - Monotherapy Phase | 0.0385 (0.024 to 0.125) | 0.1233 (0.026 to 0.149) | 0.0340 (0.021 to 0.128) | 0.0278 (0.003 to 0.994) | 5.9177 (1.884 to 14.966) |
Blood samples were collected at indicated time point for pharmacokinetic analysis of GSK3810109A.
| μg/mL | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| Plasma Concentration at Day 14 (C14) of GSK3810109A - Monotherapy Phase | 221.45 ± 23.76 | 27.49 ± 49.24 | 55.30 ± 22.08 | 7.98 ± 89.70 | 29.52 ± 54.30 |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline is defined as post-dose visit value minus baseline value. Statistical analysis for relationship between PK parameter (Cmax) and PD measure (change from baseline in logarithm to base 10 (log10) values for plasma HIV-1 RNA) were explored using an Emax non-linear model. The model parameters estimated included: maximum response (Emax), PK parameter value that attains 50 percent (%) of the maximal effect (EC50) and residual variability (s2e). End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
| Log10 copies per milliliter (copies/mL) | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV |
|---|---|---|---|---|
| Baseline (Day 1) | 4.139 ± 0.6433 | 4.493 ± 0.4800 | 4.465 ± 0.3594 | 4.582 ± 0.6144 |
| Change from baseline (up to Day 84 or end of Monotherapy Phase) | 0.091 ± 0.2359 | -0.357 ± 0.4191 | -0.110 ± 0.1940 | -0.179 ± 0.4319 |
Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
| Cells per cubic milimeter | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| CD4+, Baseline (Day 1 (Monotherapy Phase) | 360.5 ± 166.54 | 412.8 ± 120.85 | 427.3 ± 187.22 | 467.3 ± 194.45 | 476.7 ± 180.28 |
| CD4+, Day 84/end of Monotherapy Phase | 392.3 ± 196.16 | 443.0 ± 155.17 | 424.0 ± 171.33 | 412.9 ± 98.50 | 462.4 ± 276.72 |
| CD8+, Baseline (Day 1 (Monotherapy Phase) | 852.0 ± 441.83 | 884.5 ± 389.42 | 781.8 ± 303.75 | 1161.3 ± 697.24 | 898.0 ± 348.48 |
| CD8+, Day 84/End of Monotherapy Phase | 837.9 ± 482.68 | 869.8 ± 376.86 | 744.0 ± 267.73 | 993.1 ± 394.84 | 765.9 ± 296.18 |
Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry.
| Cells per cubic milimeter | SOC - GSK3810109A 40mg/kg IV | SOC - GSK3810109A 280 mg IV | SOC - GSK3810109A 700 mg IV | SOC - GSK3810109A 70 mg IV | SOC - GSK3810109A 700 mg SC |
|---|---|---|---|---|---|
| CD4+, Week 48 (SOC Phase) | 500.5 ± 211.17 | 601.0 ± 44.74 | 580.9 ± 165.29 | 671.3 ± 180.25 | 723.9 ± 300.24 |
| CD8+, Week 48 (SOC Phase) | 685.9 ± 308.89 | 738.4 ± 213.22 | 684.9 ± 286.60 | 856.0 ± 325.04 | 816.6 ± 364.40 |
Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
| Cells per cubic milimeter | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| CD4+, Baseline (Day 1 (Monotherapy Phase) | 360.5 ± 166.54 | 412.8 ± 120.85 | 427.3 ± 187.22 | 467.3 ± 194.45 | 476.7 ± 180.28 |
| CD4+, Day 84/end of Monotherapy Phase (compared with baseline) | 31.8 ± 48.27 | 30.2 ± 79.83 | -3.3 ± 125.78 | -54.3 ± 121.18 | -19.6 ± 166.64 |
| CD8+, Baseline (Day 1 (Monotherapy Phase) | 852.0 ± 441.83 | 884.5 ± 389.42 | 781.8 ± 303.75 | 1161.3 ± 697.24 | 898.0 ± 348.48 |
| CD8+, Day 84/end of Monotherapy Phase (compared with baseline) | -14.1 ± 213.24 | -14.7 ± 281.75 | -37.8 ± 206.05 | -168.2 ± 401.82 | -105.7 ± 246.85 |
Blood samples were collected as prespecified. CD4+ and CD8+ T cell counts were assessed using flow cytometry.
| Cells per cubic milimeter | SOC - GSK3810109A 40mg/kg IV | SOC - GSK3810109A 280 mg IV | SOC - GSK3810109A 700 mg IV | SOC - GSK3810109A 70 mg IV | SOC - GSK3810109A 700 mg SC |
|---|---|---|---|---|---|
| CD4+, Baseline (Day 1 (Monotherapy Phase) | 360.5 ± 166.54 | 412.8 ± 120.85 | 427.3 ± 187.22 | 467.3 ± 194.45 | 476.7 ± 180.28 |
| CD4+, Week 48 of SOC Phase (compared with baseline) | 140.0 ± 91.08 | 180.4 ± 114.37 | 134.9 ± 205.13 | 233.8 ± 174.02 | 247.3 ± 230.95 |
| CD8+, Baseline (Day 1 (Monotherapy Phase) | 852.0 ± 441.83 | 884.5 ± 389.42 | 781.8 ± 303.75 | 1161.3 ± 697.24 | 898.0 ± 348.48 |
| CD8+, Week 48 of SOC Phase (compared with baseline) | -166.1 ± 274.92 | -159.4 ± 275.37 | -119.7 ± 198.49 | -217.5 ± 490.10 | -81.4 ± 230.95 |
Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
| Participants | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| Baseline (Day 1) | 0 | 0 | 0 | 0 | 0 |
| Day 84/End of Monotherapy Phase | 1 | 2 | 0 | 3 | 0 |
Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays.
| Participants | SOC - GSK3810109A 40mg/kg IV | SOC - GSK3810109A 280 mg IV | SOC - GSK3810109A 700 mg IV | SOC - GSK3810109A 70 mg IV | SOC - GSK3810109A 700 mg SC |
|---|---|---|---|---|---|
| Number of Participants With Positive ADAs Against GSK3810109A - SOC Phase | 0 | 0 | 1 | 2 | 0 |
Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays. End of Monotherapy Phase is defined as the timepoint when a participant had reached the monotherapy endpoint criteria or a maximum of 84 days follow-up, whichever occurred first.
| Titers | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) |
|---|---|---|---|---|---|
| Titers of Positive ADAs Against GSK3810109A - Monotherapy Phase | 40 (40 to 40) | 60 (40 to 80) | — | 80 (40 to 640) | — |
Serum samples were collected to analyze the presence of ADAs against GSK3810109A using validated immunoassays.
| Titers | SOC - GSK3810109A 40mg/kg IV | SOC - GSK3810109A 280 mg IV | SOC - GSK3810109A 700 mg IV | SOC - GSK3810109A 70 mg IV | SOC - GSK3810109A 700 mg SC |
|---|---|---|---|---|---|
| Titers of Positive ADAs Against GSK3810109A - SOC Phase | — | — | 40 (40 to 40) | 160 (160 to 160) | — |
Collected over All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to 12 weeks for Monotherapy Phase (Part 1 and Part 2 groups) and up to 48 weeks for SOC Phase (SOC groups).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Part 1: GSK3810109A 280 mg IV | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 2: GSK3810109A 700 mg IV | 0/16 (0%) | 0/16 (0%) | 9/16 (56.3%) |
| Part 2: GSK3810109A 70 mg IV | 0/16 (0%) | 0/16 (0%) | 8/16 (50%) |
| Part 2: GSK3810109A 700 mg Subcutaneously (SC) | 0/16 (0%) | 0/16 (0%) | 11/16 (68.8%) |
| SOC - GSK3810109A 40mg/kg IV | 0/8 (0%) | 1/8 (12.5%) | 8/8 (100%) |
| SOC - GSK3810109A 280 mg IV | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| SOC - GSK3810109A 700 mg IV | 0/16 (0%) | 3/16 (18.8%) | 12/16 (75%) |
| SOC - GSK3810109A 70 mg IV | 0/16 (0%) | 2/16 (12.5%) | 13/16 (81.3%) |
| SOC - GSK3810109A 700 mg SC | 0/16 (0%) | 4/16 (25%) | 14/16 (87.5%) |
| Event | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) | SOC - GSK3810109A 40mg/kg IV | SOC - GSK3810109A 280 mg IV | SOC - GSK3810109A 700 mg IV | SOC - GSK3810109A 70 mg IV | SOC - GSK3810109A 700 mg SC |
|---|---|---|---|---|---|---|---|---|---|---|
| Suicide attemptPsychiatric disorders | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 | 1/8 | 0/6 | 1/16 | 0/16 | 1/16 |
| AppendicitisInfections and infestations | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 | 0/8 | 0/6 | 1/16 | 0/16 | 0/16 |
| Scrotal abscessInfections and infestations | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 | 0/8 | 0/6 | 1/16 | 0/16 | 0/16 |
| Craniocerebral injuryInjury, poisoning and procedural complications | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 | 0/8 | 0/6 | 0/16 | 0/16 | 1/16 |
| Radius fractureInjury, poisoning and procedural complications | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 | 0/8 | 0/6 | 0/16 | 0/16 | 1/16 |
| Wrist fractureInjury, poisoning and procedural complications | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 | 0/8 | 0/6 | 0/16 | 0/16 | 1/16 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 | 0/8 | 0/6 | 1/16 | 0/16 | 0/16 |
| Inguinal herniaGastrointestinal disorders | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 | 0/8 | 0/6 | 0/16 | 1/16 | 0/16 |
| Human rhinovirus test positiveInvestigations | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 | 0/8 | 0/6 | 0/16 | 0/16 | 1/16 |
| DehydrationMetabolism and nutrition disorders | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 | 0/8 | 0/6 | 0/16 | 1/16 | 0/16 |
| Event | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) | SOC - GSK3810109A 40mg/kg IV | SOC - GSK3810109A 280 mg IV | SOC - GSK3810109A 700 mg IV | SOC - GSK3810109A 70 mg IV | SOC - GSK3810109A 700 mg SC |
|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 1/8 | 0/6 | 0/16 | 2/16 | 0/16 | 2/8 | 0/6 | 1/16 | 0/16 | 0/16 |
| Proctitis gonococcalInfections and infestations | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 | 2/8 | 0/6 | 0/16 | 0/16 | 0/16 |
| SyphilisInfections and infestations | 0/8 | 1/6 | 0/16 | 0/16 | 0/16 | 2/8 | 0/6 | 0/16 | 1/16 | 0/16 |
| Upper respiratory tract infectionInfections and infestations | 0/8 | 0/6 | 1/16 | 0/16 | 0/16 | 1/8 | 0/6 | 3/16 | 2/16 | 2/16 |
| HeadacheNervous system disorders | 1/8 | 0/6 | 1/16 | 1/16 | 3/16 | 1/8 | 0/6 | 0/16 | 1/16 | 1/16 |
| Abdominal painGastrointestinal disorders | 1/8 | 1/6 | 0/16 | 0/16 | 0/16 | 1/8 | 0/6 | 0/16 | 1/16 | 0/16 |
| DyspepsiaGastrointestinal disorders | 0/8 | 1/6 | 0/16 | 0/16 | 1/16 | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 |
| Inguinal herniaGastrointestinal disorders | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 | 0/8 | 1/6 | 0/16 | 0/16 | 0/16 |
| NauseaGastrointestinal disorders | 0/8 | 1/6 | 1/16 | 0/16 | 1/16 | 0/8 | 0/6 | 0/16 | 0/16 | 1/16 |
| AstheniaGeneral disorders | 0/8 | 1/6 | 0/16 | 0/16 | 0/16 | 0/8 | 0/6 | 0/16 | 0/16 | 0/16 |
| Age, Continuous(YEARS) | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) | Total |
|---|---|---|---|---|---|---|
| Mean | 34.3 ± 9.39 | 34.0 ± 14.83 | 31.2 ± 10.46 | 32.3 ± 10.33 | 31.5 ± 11.08 | 32.2 ± 10.62 |
| Sex/Gender, Customized(Participants) | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 1 | 2 | 0 | 1 | 4 |
| Male | 8 | 5 | 14 | 16 | 15 | 58 |
| Race/Ethnicity, Customized(Participants) | Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) | Part 1: GSK3810109A 280 mg IV | Part 2: GSK3810109A 700 mg IV | Part 2: GSK3810109A 70 mg IV | Part 2: GSK3810109A 700 mg Subcutaneously (SC) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 2 | 1 | 3 |
| Black or African American | 2 | 1 | 3 | 3 | 2 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 1 |
| White - Arabic/ North African Heritage | 0 | 0 | 0 | 1 | 3 | 4 |
| White - White/ Caucasian/ European Heritage | 6 | 5 | 10 | 8 | 9 | 38 |
| Multiple | 0 | 0 | 3 | 1 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Jun 2021 to primary completion in Oct 2022, 16 months.
Results were first posted in Nov 2023, 1 year after primary completion.
Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 16 months is below that.
Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.